



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Khan et al.

Serial No.: 10/028,075

Filed: December 21, 2001

For: GENE REGULATOR

Confirmation No.: 1102

Examiner: T. McKelvey

Group Art Unit: 1632

Attorney Docket No.: 2183-5223US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV 326919425 US

Date of Deposit with USPS: October 28, 2003

Person making Deposit: Christopher Haughton

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08A be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US - 5,968,513	10/19/1999	Gallo et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
EP 1 138 692 A1	10/04/2001	Erasmus Universiteit Rotterdam

Other Documents

ALBINI, A., et al., "Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin," 17 CLINICAL & EXPERIMENTAL METASTASIS 739 (1999).

BLACKWELL, Timothy S., et al., "The Role of Nuclear Factor- κ B in Cytokine Gene Regulation," 17 AM. J. RESPIR. CELL MOL. BIOL. 3-9 (1997).

KELLER, S., et al., "Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells *in Vitro*," 20(5-6) PLACENTA, page A37 (July 1999).

KHAN, Nisar A., et al., "Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor," 62(12) HUMAN IMMUNOLOGY 1315-1323 (December 2001).

KHAN, Nisar A., et al., "Inhibition of Septic Shock in Mice by an Oligopeptide From the β -Chain of Human Chorionic Gonadotrophin Hormone," 63(1) HUMAN IMMUNOLOGY 1-7 (January 2002).

PATIL, A., et al., "The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study," 87 ACTA NEUROCHIR (WIEN) 76-78 (1987).

SLATER, Lewis M., "Decreased Mortality of Murine Graft-Versus-Host Disease by Human Chorionic Gonadotropin," 23(1) TRANSPLANTATION 103-104 (January 1977).

Other Documents

WULCZYN, F. Gregory, et al., "The NF- κ B/Rel and I κ B gene families: mediators of immune response and inflammation," 74(12) J. MOL. MED. 749-769 (1996).

YAMAMOTO, Y., et al., "Role of the NF- κ B Pathway in the Pathogenesis of Human Disease States," 1(3) CURRENT MOLECULAR MEDICINE 287-296 (July 2001).

International Search Report, International Application No. PCT/NL02/00639, mailed August 4, 2003 (8 pages).

Applicants offer to supply any explanation or discussion of the documents which the Examiner feels is necessary or desirable and which is requested.

This Supplemental Information Disclosure Statement is filed before the mailing date of the first Office Action on the merits; however, should a fee be required, please debit Deposit Account No. 20-1469.

I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, and therefore no fee is due.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 28, 2003
ACT/jml

Enclosures: Form PTO/SB/08A
Copies of documents cited



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

f 2

Attorney Docket Number

Complete if Known

Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1632
Examiner Name	T. McKelvey

Shee

1

f 2

2183-5223US

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2 of 2

Complete if Known

Application Number	10/028,075
Filing Date	December 21, 2001
First Named Inventor	Khan et al.
Group Art Unit	1632
Examiner Name	T. McKelvey
Attorney Docket Number	2183-5223US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ALBINI, A., et al., "Old drugs as novel angiogenesis inhibitors: Preclinical studies with NAC, hCG, EGCG and somatostatin," 17 CLINICAL & EXPERIMENTAL METASTASIS 739 (1999).	
		BLACKWELL, Timothy S., et al., "The Role of Nuclear Factor- κ B in Cytokine Gene Regulation," 17 AM. J. RESPIR. CELL MOL. BIOL. 3-9 (1997).	
		KELLER, S., et al., "Human Chorionic Gonadotropin (hCG) Is a Potent Angiogenic Factor for Uterine Endothelial Cells <i>in Vitro</i> ," 20(5-6) PLACENTA, page A37 (July 1999).	
		KHAN, Nisar A., et al., "Inhibition of Diabetes in NOD Mice by Human Pregnancy Factor," 62(12) HUMAN IMMUNOLOGY 1315-1323 (December 2001).	
		KHAN, Nisar A., et al., "Inhibition of Septic Shock in Mice by an Oligopeptide From the β -Chain of Human Chorionic Gonadotrophin Hormone," 63(1) HUMAN IMMUNOLOGY 1-7 (January 2002).	
		PATIL, A., et al., "The Study of the Effect of Human Chorionic Gonadotrophic (HCG) Hormone on the Survival of Adrenal Medulla Transplant in Brain. Preliminary Study," 87 ACTA NEUROCHIR (WIEN) 76-78 (1987).	
		SLATER, Lewis M., et al., "Decreased Mortality of Murine Graft-Versus-Host Disease by Human Chorionic gonadotropin, "23(1) TRANSPLANTATION 103-104 (January 1977).	
		WULCZYN, F. Gregory, et al., "The NF- κ B/Rel and I κ B gene families: mediators of immune response and inflammation," 74(12) J. MOL. MED. 749-769 (1996).	
		YAMAMOTO, Y., et al., "Role of the NF- κ B Pathway in the Pathogenesis of Human Disease States," 1(3) CURRENT MOLECULAR MEDICINE 287-296 (July 2001).	
		International Search Report, International Application No. PCT/NL02/00639, mailed August 4, 2003 (8 pages).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.